The needle-free drug delivery devices market size has grown exponentially in recent years. It will grow from $14.99 billion in 2023 to $16.7 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed during the historic period can be attributed to several factors, including the increased prevalence of chronic diseases, heightened demand for painless drug delivery methods, a growing geriatric population, emphasis on patient compliance and safety, regulatory support for needle-free technologies, and expansion within the pharmaceutical industry.
The needle-free drug delivery devices market size is expected to see exponential growth in the next few years. It will grow to $25.88 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to several factors, including increasing demand for painless medication administration, a growing emphasis on patient-centric healthcare solutions, expanding applications in pediatric and geriatric populations, rising prevalence of chronic diseases requiring frequent injections, technological advancements enhancing device efficiency and usability, expanding access to healthcare in emerging markets, and growing investments in research and development for innovative delivery systems. Major trends expected during this period include increased adoption of wearable and connected devices, the emergence of novel microfluidic technologies, a growing focus on pediatric-friendly needle-free solutions, integration of artificial intelligence and machine learning algorithms, and expanding applications in home healthcare settings.
The rise in diabetes prevalence is anticipated to drive the expansion of the needle-free drug delivery device market in the foreseeable future. Diabetes, characterized by elevated blood sugar levels due to insufficient insulin production or ineffective insulin utilization, persists as a significant health concern. Sedentary lifestyles, poor dietary habits, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates contribute to the growing incidence of diabetes globally. Needle-free drug delivery devices offer an alternative to traditional injections for administering insulin in diabetes management. These devices utilize technologies such as jet injectors or transdermal patches to deliver insulin through the skin without needles, mitigating the discomfort and anxiety associated with injections and improving patient comfort. For instance, the International Diabetes Federation reported in July 2021 that the projected number of individuals living with diabetes is expected to reach 643 million by 2030 and 783 million by 2045, highlighting the upward trend in diabetes prevalence. Consequently, the rising prevalence of diabetes is propelling the growth of the needle-free drug delivery device market.
Prominent companies in the needle-free drug delivery device market are concentrating on innovative solutions such as dual-chamber inhalers to enhance effectiveness and ease of administration, addressing the evolving needs of patients and healthcare providers. A dual-chamber inhaler comprises two compartments capable of holding different medications separately, facilitating the combination of multiple drugs in a single device for streamlined treatment and enhanced patient convenience. For instance, Berry Global, a US-based plastic manufacturing company, introduced the BerryHaler in April 2024, a state-of-the-art dry powder inhaler (DPI) designed to revolutionize patient-centered healthcare solutions. Equipped with a dose counter, this dual-chamber inhaler ensures precise medication administration and features an all-plastic construction devoid of metal parts, ideal for complex inhalation treatments. Advanced functionalities such as a bi-directional mouthpiece cover for convenience and hygiene, along with audible signals indicating proper usage, enhance user experience. The integrated dose counter facilitates accurate monitoring of medication usage, minimizing dosage errors.
In May 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million, aiming to strengthen its position as a leading drug delivery company. Leveraging Antares' auto-injector platform and specialty commercial business, Halozyme expands its strategy to include specialty products, accelerating long-term revenue growth. Antares Pharma Inc., a US-based pharmaceutical company, specializes in developing needle-free injectors used for insulin delivery in diabetes treatment.
Major companies operating in the needle-free drug delivery devices market are Pfizer Inc., Merck & Co. Inc., Bayer AG, 3M Company, Medtronic plc, Novo Nordisk AS, Becton, Dickinson and Company, Endo International plc, Insulet Corporation, Purdue Pharma L.P., Antares Pharma Inc., MannKind Corporation, Med-Jet Inc., Portal Instruments, PharmaJet, Inovio Pharmaceuticals, Inc., National Medical Products Inc., Mika Medical Co. Ltd., Medical International Technology Inc. (MTI), NanoPass Technologies Ltd., PenJet Corporation, Akra Dermojet S.A., NuGen Medical Devices Inc., Crossject SA, Injex Pharma AG.
North America was the largest region in the needle-free drug delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the needle-free drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the needle-free drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Needle-free drug delivery devices are medical tools designed to administer medication without the use of traditional needles. They provide an alternative method for delivering drugs, vaccines, or therapeutic agents into the body through the skin or mucosal membranes, aiming to reduce patient discomfort and the risk of needle-related injuries.
The primary types of needle-free drug delivery devices include inhalers, jet injectors, novel needles, transdermal patches, and others. Inhalers are portable devices that deliver medication directly into the lungs through a mist or spray. They find applications in various areas such as pain management, vaccine delivery, pediatric injections, insulin delivery, among others, and are utilized by a range of end-users including hospitals and clinics, as well as home healthcare settings.
The needle-free drug delivery devices market research report is one of a series of new reports that provides needle-free drug delivery devices market statistics, including needle-free drug delivery devices industry global market size, regional shares, competitors with a needle-free drug delivery devices market share, detailed needle-free drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the needle-free drug delivery devices industry. This needle-free drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The needle-free drug delivery devices market consists of sales of nasal sprays, buccal patches, and oral inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The needle-free drug delivery devices market size is expected to see exponential growth in the next few years. It will grow to $25.88 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to several factors, including increasing demand for painless medication administration, a growing emphasis on patient-centric healthcare solutions, expanding applications in pediatric and geriatric populations, rising prevalence of chronic diseases requiring frequent injections, technological advancements enhancing device efficiency and usability, expanding access to healthcare in emerging markets, and growing investments in research and development for innovative delivery systems. Major trends expected during this period include increased adoption of wearable and connected devices, the emergence of novel microfluidic technologies, a growing focus on pediatric-friendly needle-free solutions, integration of artificial intelligence and machine learning algorithms, and expanding applications in home healthcare settings.
The rise in diabetes prevalence is anticipated to drive the expansion of the needle-free drug delivery device market in the foreseeable future. Diabetes, characterized by elevated blood sugar levels due to insufficient insulin production or ineffective insulin utilization, persists as a significant health concern. Sedentary lifestyles, poor dietary habits, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates contribute to the growing incidence of diabetes globally. Needle-free drug delivery devices offer an alternative to traditional injections for administering insulin in diabetes management. These devices utilize technologies such as jet injectors or transdermal patches to deliver insulin through the skin without needles, mitigating the discomfort and anxiety associated with injections and improving patient comfort. For instance, the International Diabetes Federation reported in July 2021 that the projected number of individuals living with diabetes is expected to reach 643 million by 2030 and 783 million by 2045, highlighting the upward trend in diabetes prevalence. Consequently, the rising prevalence of diabetes is propelling the growth of the needle-free drug delivery device market.
Prominent companies in the needle-free drug delivery device market are concentrating on innovative solutions such as dual-chamber inhalers to enhance effectiveness and ease of administration, addressing the evolving needs of patients and healthcare providers. A dual-chamber inhaler comprises two compartments capable of holding different medications separately, facilitating the combination of multiple drugs in a single device for streamlined treatment and enhanced patient convenience. For instance, Berry Global, a US-based plastic manufacturing company, introduced the BerryHaler in April 2024, a state-of-the-art dry powder inhaler (DPI) designed to revolutionize patient-centered healthcare solutions. Equipped with a dose counter, this dual-chamber inhaler ensures precise medication administration and features an all-plastic construction devoid of metal parts, ideal for complex inhalation treatments. Advanced functionalities such as a bi-directional mouthpiece cover for convenience and hygiene, along with audible signals indicating proper usage, enhance user experience. The integrated dose counter facilitates accurate monitoring of medication usage, minimizing dosage errors.
In May 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million, aiming to strengthen its position as a leading drug delivery company. Leveraging Antares' auto-injector platform and specialty commercial business, Halozyme expands its strategy to include specialty products, accelerating long-term revenue growth. Antares Pharma Inc., a US-based pharmaceutical company, specializes in developing needle-free injectors used for insulin delivery in diabetes treatment.
Major companies operating in the needle-free drug delivery devices market are Pfizer Inc., Merck & Co. Inc., Bayer AG, 3M Company, Medtronic plc, Novo Nordisk AS, Becton, Dickinson and Company, Endo International plc, Insulet Corporation, Purdue Pharma L.P., Antares Pharma Inc., MannKind Corporation, Med-Jet Inc., Portal Instruments, PharmaJet, Inovio Pharmaceuticals, Inc., National Medical Products Inc., Mika Medical Co. Ltd., Medical International Technology Inc. (MTI), NanoPass Technologies Ltd., PenJet Corporation, Akra Dermojet S.A., NuGen Medical Devices Inc., Crossject SA, Injex Pharma AG.
North America was the largest region in the needle-free drug delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the needle-free drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the needle-free drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Needle-free drug delivery devices are medical tools designed to administer medication without the use of traditional needles. They provide an alternative method for delivering drugs, vaccines, or therapeutic agents into the body through the skin or mucosal membranes, aiming to reduce patient discomfort and the risk of needle-related injuries.
The primary types of needle-free drug delivery devices include inhalers, jet injectors, novel needles, transdermal patches, and others. Inhalers are portable devices that deliver medication directly into the lungs through a mist or spray. They find applications in various areas such as pain management, vaccine delivery, pediatric injections, insulin delivery, among others, and are utilized by a range of end-users including hospitals and clinics, as well as home healthcare settings.
The needle-free drug delivery devices market research report is one of a series of new reports that provides needle-free drug delivery devices market statistics, including needle-free drug delivery devices industry global market size, regional shares, competitors with a needle-free drug delivery devices market share, detailed needle-free drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the needle-free drug delivery devices industry. This needle-free drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The needle-free drug delivery devices market consists of sales of nasal sprays, buccal patches, and oral inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Needle-Free Drug Delivery Devices Market Characteristics3. Needle-Free Drug Delivery Devices Market Trends and Strategies32. Global Needle-Free Drug Delivery Devices Market Competitive Benchmarking33. Global Needle-Free Drug Delivery Devices Market Competitive Dashboard34. Key Mergers and Acquisitions in the Needle-Free Drug Delivery Devices Market
4. Needle-Free Drug Delivery Devices Market - Macro Economic Scenario
5. Global Needle-Free Drug Delivery Devices Market Size and Growth
6. Needle-Free Drug Delivery Devices Market Segmentation
7. Needle-Free Drug Delivery Devices Market Regional and Country Analysis
8. Asia-Pacific Needle-Free Drug Delivery Devices Market
9. China Needle-Free Drug Delivery Devices Market
10. India Needle-Free Drug Delivery Devices Market
11. Japan Needle-Free Drug Delivery Devices Market
12. Australia Needle-Free Drug Delivery Devices Market
13. Indonesia Needle-Free Drug Delivery Devices Market
14. South Korea Needle-Free Drug Delivery Devices Market
15. Western Europe Needle-Free Drug Delivery Devices Market
16. UK Needle-Free Drug Delivery Devices Market
17. Germany Needle-Free Drug Delivery Devices Market
18. France Needle-Free Drug Delivery Devices Market
19. Italy Needle-Free Drug Delivery Devices Market
20. Spain Needle-Free Drug Delivery Devices Market
21. Eastern Europe Needle-Free Drug Delivery Devices Market
22. Russia Needle-Free Drug Delivery Devices Market
23. North America Needle-Free Drug Delivery Devices Market
24. USA Needle-Free Drug Delivery Devices Market
25. Canada Needle-Free Drug Delivery Devices Market
26. South America Needle-Free Drug Delivery Devices Market
27. Brazil Needle-Free Drug Delivery Devices Market
28. Middle East Needle-Free Drug Delivery Devices Market
29. Africa Needle-Free Drug Delivery Devices Market
30. Needle-Free Drug Delivery Devices Market Competitive Landscape and Company Profiles
31. Needle-Free Drug Delivery Devices Market Other Major and Innovative Companies
35. Needle-Free Drug Delivery Devices Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Needle-Free Drug Delivery Devices Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on needle-free drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for needle-free drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The needle-free drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Device Type: Inhalers; Jet Injectors; Novel Needles; Transdermal Patches; Other Device Types2) By Application: Pain Management; Vaccine Delivery; Pediatric Injections; Insulin Delivery; Other Applications
3) By End-User: Hospitals And Clinics; Home Healthcare
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; 3M Company; Medtronic plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Merck & Co. Inc.
- Bayer AG
- 3M Company
- Medtronic plc
- Novo Nordisk AS
- Becton, Dickinson and Company
- Endo International plc
- Insulet Corporation
- Purdue Pharma L.P.
- Antares Pharma Inc.
- MannKind Corporation
- Med-Jet Inc.
- Portal Instruments
- PharmaJet
- Inovio Pharmaceuticals, Inc.
- National Medical Products Inc.
- Mika Medical Co. Ltd.
- Medical International Technology Inc. (MTI)
- NanoPass Technologies Ltd.
- PenJet Corporation
- Akra Dermojet S.A.
- NuGen Medical Devices Inc.
- Crossject SA
- Injex Pharma AG
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 16.7 Billion |
Forecasted Market Value ( USD | $ 25.88 Billion |
Compound Annual Growth Rate | 11.6% |
Regions Covered | Global |